

Container Closure Integrity: Regulations, Test Methods, Application – Regulatory Requirements



CONNECTING PEOPLE SCIENCE AND REGULATION®

Meet the Instructors -



Eli Lilly and Company; coralie.richard@lilly.com



Eli Lilly and Company; dillal@lilly.com

With significant contribution from Dr. Dana M. Guazzo PhD, RxPax, LLC, dguazzo@rxpax.com



pda.org







WELCOME

- Introduction
 - Your name and company
 - Your position and how it relates to CCI
 - Goals and expectations for the short course
- Group Discussion (VoC)
 - What are the needs and pain you experienced?
 - How can this course help you?





FDA Guidelines



Food and Drug Cosmetic Act

- 1962 Amendments added cGMP provision, Section 501 (a) (3)
 - "A drug ... shall be deemed to be adulterated if... its container is composed, in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health"

The Regulations:

- 21 CFR § 600.11 (h)
 - After filling, sealing shall be performed in a manner that will maintain the integrity of the product during the dating period. In addition, final containers and closures for products intended for use by injection shall be sterile and free from pyrogens.
- 21 CFR § 211.94 (b)

Container closure systems shall provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.





Eval.

CC

Stability

Industry Consensus

Container Closure Integrity

According to US FDA (1999). Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics –

 Container closure integrity is considered an essential part of suitability, especially in the aspect of protection against microbial contamination, reactive gases (e.g., oxygen), and moisture.







Process Val. CCI Eval.

CCI Eval

Prod. Dev.

Mfg. Batch CCI Eval.






Container Closure Integrity

Industry Consensus Stability CCI Eval. Mfg. Batch CCI Eval. • • • • • • •

According to US FDA (1999). Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics –

- A container closure system that permits penetration of microorganisms is unsuitable for a sterile product.
- It requires suitability of the selected container closure system be sufficiently established in the four key aspects: protection, safety, compatibility, and performance.







pda.org





Product Development CCI Evaluation



ICH Q8(R2) (2009) Pharmaceutical Development: The choice of materials for primary packaging should be **justified**. The discussion should describe studies performed to demonstrate the integrity of the container and closure. A possible interaction between product and container or label should be considered.



CCI Eval

Val.

Process

Mfg. Batch CCI Eval.



Product Development CCI Evaluation

US FDA (1994). Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products

- Study designs should simulate the stresses of the sterilization process, handling, and storage of the drug and their effects on the container-closure system.
- Container-closure integrity should be demonstrated on product units that have been exposed to the maximum sterilization cycle(s). If a product is exposed to more than one process, then exposure to the maximum cycle of all processes should be incorporated into the study design. The studies must be described and included in the submission to gain regulatory approval.





Process Validation CCI Evaluation

US FDA (1994). Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products

- For <u>initial validation</u> of microbiological integrity of container-closure systems, product sterility testing is not normally considered sufficient. Container closure integrity testing methods and results should be summarized to demonstrate the integrity of the microbiological barrier.
- The ability of the container-closure system to maintain the integrity of its microbial barrier, and, hence, the sterility of a drug product <u>throughout its shelf life</u>, should be demonstrated.





FDA U.S. FOOD & DRUG

Mfg. Batch CCI Eval

Industry Consensus

Eval.

ວິວ

Stability

Process Validation CCI Evaluation

US FDA (1994). Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products

- As previously stated, sterility testing at the initial time point is not considered sufficient to demonstrate the microbial integrity of a container-closure system. Documentation of the sensitivity of the container-closure integrity test should be provided.
- The <u>sensitivity</u> of the experimental method used for container-closure integrity testing should be specified and provided.



pda.org



Mfg. Batch CCI Evaluation



EU Guideline to Good Manufacturing Practice (2009)

Medicinal Products for Human and Veterinary Use, Annex 1. Manufacturer of Sterile Medicinal Products.

Previous Wording:

117. Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g., glass or plastic ampoules should be subject to <u>100% integrity testing</u>. Samples of other containers should be checked for integrity according to <u>appropriate procedures</u>.





CONNECTING PFOPIF



Mfg. Batch CCI Evaluation

EU Guideline to Good Manufacturing Practice (2022)

SCIENCE MEDICINES HEALTH

Medicinal Products for Human and Veterinary Use, Annex 1. Manufacturer of Sterile Medicinal Products.

8.21 Final containers should be closed by appropriately validated methods.

8.22 Where final containers are closed by fusion, e.g. Blow-Fill-Seal (BFS), Form-Fill-Seal (FFS), Small and Large Volume Parenteral (SVP & LVP) bags, glass or plastic ampoules, the critical parameters and variables that affect seal integrity should be evaluated, determined, effectively controlled and monitored during operations. Glass ampoules, BFS units and small volume containers (\leq 100 ml) closed by fusion should be subject to 100% integrity testing using validated methods. For large volume containers (> 100 ml) closed by fusion, reduced sampling may be acceptable where scientifically justified and based on data demonstrating the consistency of the existing process, and a high level or process control. It should be noted that visual inspection is not considered as an acceptable integrity test method.

8.23 Samples of products using systems other than fusion should be taken and checked for integrity using validated methods. The frequency of testing should be based on the knowledge and experience of the container and closure system being used. A scientifically justified sampling plan should be used. The sample size should be based on information such as supplier management, packaging component specifications and process knowledge.

Eval.

Stability CCI



Mfg. Batch CCI Evaluation

EU Guideline to Good Manufacturing Practice (2022)

Medicinal Products for Human and Veterinary Use, Annex 1. Manufacturer of Sterile Medicinal Products.

8.25 The container closure integrity validation should take into consideration any transportation or shipping requirements that may negatively impact the integrity of the container (e.g., by decompression or temperature extremes).



Industry Consensus





Mfg. Batch CCI **Evaluation**



U.S. Food and Drug Administration Protecting and Promoting Your Health

US FDA (2004). Guidance for Industry Sterile Drug Products Produced by Aseptic Processing — **Current Good Manufacturing Practice**

For drug products produced by aseptic processing, US FDA cGMP guidance requires any damaged or defective units should be detected, and removed, during inspection of the final sealed product.





Routine Stability CCI Evaluation

US State Food and Drug Administration (2008)

ICH Q5C Guidance for the industry

Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products

- US FDA promotes container and closure system integrity (CCI) testing as a component of the stability protocol for sterile products.
- The guidance recommended CCI testing on stability in lieu of traditional end-of-shelf-life sterility testing for better sterility assurance, especially continued sterility of a drug product.
- The guidance requires stability CCI testing methods be appropriately validated.





Routine Stability CCI Evaluation

US State Food and Drug Administration (2008)

ICH Q5C Guidance for the industry

Quality of Biotechnological products: Stability testing of Biotechnological / Biological products"

• Sterility testing or alternatives (e.g., container closure integrity testing) should be performed at a minimum initially and at the end of the proposed shelf-life.





ISO 11608-3

4.2.1 Container Closure Integrity (CCI)

Container closure integrity shall be ensured until the expiration date of the first intentional user interaction that breaks CCI.

If the NIS is manufacture- assembled with a primary container closure to form a single integral unit, the manufacturing processes, including assembly, shall be shown to not adversely impact container closure integrity, in accordance with applicable pharmacopeia.





Industry Consensus Guidance & Best Practices













The suitability of a container closure system should be established in which key aspects? □ Protection **D**imensions □ Safety □ Compatibility □ Performance





Which USP guidance talks about Package Integrity Evaluation – Sterile Products?



USP 659

USP 671

USP 661







PDA TR86 Revision (Published May 2021)


- 1.0 INTRODUCTION
- 2.0 Glossary
- 3.0 Challenges with Methodologies 3.1 Positive Controls
 - 3. I Positive Controls
 - 3.2 Blockage of Leak Paths
- 4.0 Challenges with Package Design
 - 4.1 Prefilled Syringes
 - 4.2 Single-Use Systems Flexible Bulk Containers
 - 4.3 IV Bags Flexible Finished Pharmaceutical Packaging Systems
 - 4.4 Cryogenic Conditions
- 5.0 Innovative Methods for Existing Technologies
 - 5.1 Helium Testing
 - 5.2 Optical Emission Spectroscopy
 - 5.3 Airborne Ultrasounds
 - 5.2 X-Ray Detection
- 6.0 Additional Considerations for Package Integrity Profiling
 - 6.1 Transportation and Distribution
 - 6.2 100% Online Testing
 - 6.3 Building a Quality by Design Approach into the Container Closure Integrity Testing Program
 - 6.4 Bulk Container Lifecycle Approach
 - 6.5 Educational Simulation about Limits of Detection and Method Selection
- 7.0 Conclusion
- 8.0 References
- 9.0 Additional Reading





COURSE OUTLINE

Container Closure Integrity: Regulations, Test Methods, Applications







Instructors' Perspective: What We Can Deliver

- A scientific foundation for understanding and applying various CCIT technologies
 - Working principles, advantages and disadvantages
 - Technical considerations for method selection
 - Application case studies
- A risk-based approach to applying CCIT throughout product life cycle
 - CCI data package during development, validation, routine manufacturing
 - Key considerations for developing testing requirements, study design, method selection, and sampling plan
- Method development and validation best practices
- <u>Focus:</u> Enable you to make sound technical decisions to support business needs





Instructors' Perspective: What We Can NOT Deliver

- "What hole size do I need to detect?"
- A one-size-fits-all or ideal CCIT technology that is capable of covering all CCI testing needs.
- A decision tree or cheat sheet for method selection, sampling plan.

